olmesartan medoxomil and amlodipine
Regulatory sources consulted
- OpenFDA · C09DB02
- AEMPS CIMA · nº registro 70091 ↗
Approved indications
- Essential hypertension in adults whose blood pressure is not adequately controlled with olmesartan medoxomil or amlodipine monotherapy.
Contraindications
Absolute
- Hypersensitivity to the active substances, dihydropyridine derivatives, or excipients.
- Second or third trimester of pregnancy.
- Severe hepatic impairment or biliary obstruction.
- Severe hypotension, shock, severe left-ventricular outflow obstruction, or unstable heart failure after acute infarction.
Clinical warnings
- Major warning · Correct volume or sodium depletion; symptomatic hypotension may occur, particularly after the first dose. — CIMA registro 70091
- Major warning · Monitor blood pressure, renal function, and potassium; dual RAAS blockade increases hypotension, hyperkalemia, and acute renal failure. — CIMA registro 70091
Drug interactions
- HighLithium
Mechanism: May increase serum lithium concentration and toxicity.
Recommendation: Not recommended; if required, closely monitor serum lithium.
https://cima.aemps.es/cima/dochtml/ft/70091/FT_70091.html
- ModerateNSAIDs, including COX-2 inhibitors
Mechanism: May attenuate the antihypertensive effect and increase renal impairment and potassium.
Recommendation: Ensure hydration and monitor renal function and potassium.
https://cima.aemps.es/cima/dochtml/ft/70091/FT_70091.html
Adverse events
Common (≥1%)
Peripheral edema (11.3%) · Headache (5.3%) · Dizziness (4.5%)
Rare but serious
Angioedema · Acute renal failure · Shock or severe hypotension
Pregnancy and lactation
Use is not recommended in the first trimester and is contraindicated in the second and third; switch to an alternative if pregnancy is planned or detected. During breastfeeding, a treatment with better-established safety is preferred.